Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2009 Sep 15;19(18):5440-3. doi: 10.1016/j.bmcl.2009.07.102. Epub 2009 Jul 25.

Disubstituted pyrimidines as Lck inhibitors.

Author information

1
Merck Research Laboratories, Merck & Co., PO Box 2000, Rahway, NJ 07065, United States. julianne_hunt@merck.com

Abstract

We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cellular IL2 release.

PMID:
19674899
DOI:
10.1016/j.bmcl.2009.07.102
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center